Managed Care


As pharmacies begin to look at how they will be paid for their efforts to effectively manage the growing number of specialty products under health care reform, mergers and acquisitions are accelerating in an effort to broaden resources.

As they evaluate the performance of their health care vendors, employers are focusing less on cost and more on performance: What are the outcomes for the money they're spending? 

F. Randy Vogenberg, PhD, RPh: The growth of specialty pharmacy products and changing ownership patterns for medical practices can complicate delivery and administration of some patients’ treatments.

Despite the convenience of smartphones, tablets, and the many applications they offer to aid physicians, some health care experts are worried about the concerns mobile devices may raise relating to consistency, accuracy, security, and synchronization with other platforms, says F. Randy Vogenberg, RPh, PhD.

Pressure related in part to health care reform has encouraged narrow networks that not only help limit costs but also improve safety by promoting greater consistency and patient education, particularly with specialty products. — F. Randy Vogenberg, PhD, RPh

Electronic health records have progressed further in hospitals and health systems than they have in doctors' offices and pharmacies; financial and technical difficulties continue to slow full implementation warns F. Randy Vogenberg, PhD, RPh.

In the rapidly evolving market for hepatitis C virus treatments, much more effective medications with higher price tags will require careful cost-benefit analyses, says F. Randy Vogenberg, PhD, RPh.

F. Randy Vogenberg, PhD, RPh: Given the high costs of specialty drugs, sponsors of health plans (especially self-funded ones) are gathering information on costs, benefits, and outcomes to determine what kinds of coverage to offer.


“I am definitely excited about where primary care is going,” says the founding dean of the Jefferson School of Population Health, and the Dr. Raymond C. and Doris N. Grandon Professor of Health Policy at Thomas Jefferson University. Here he speaks with John Marcille, editor of Managed Care, and Sonja Sherritze, editor of P&T, about what drives his enthusiasm.

Randy Vogenberg, PhD: The differences among the latest diabetes medications are seen as less than dramatic, creating questions about the costs and benefits of the various new treatment options. Meanwhile, patient compliance remains a concern.

F. Randy Vogenberg, PhD, RPh: Contrary to its intent, the Affordable Care Act has decreased access to primary care physicians while at the same time reducing support for the education of new doctors who could help relieve that problem.